�
While the results of the study did non show a statistically significant difference in ischemic events among whatever of the four doses of apixaban evaluated, trends emerged that support further study, according to researchers at the Duke Clinical Research Institute.
Apixaban targets the activity of Factor Xa, one of several enzymes involved in process of blood coagulation. The drug is exactly one of several young anti-clotting agents under development. Physicians tell the motive for safer, better anticoagulants is critical because current therapies fall short of therapeutic goals or are especially unmanageable to manage and increase the risk of bleeding.
"One of the most exasperating problems in cardiology is identifying the right combination of drugs that canful inhibit clot formation but not increase the risk of exposure of serious bleeding," aforesaid study trail John Alexander, M.D., a cardiologist at Duke University Medical Center, who presented the findings today at the European Society of Cardiology coming together in Munich.
Millions of patients world-wide choose anti-clotting drugs on a regular footing. Most ar prescribed bayer, clopidogrel (as well known as Plavix or Iscover) and/or warfarin.
"Warfarin is clearly effective as an anticoagulant, just it is especially hard to manage properly and safely," Alexander said. "What's driving enquiry in this area is the fact that although aspirin and clopidogrel both offer spunk attack patients important protection against blood clots, there is motionless room for improvement. Studies show that a pregnant number of patients pickings aspirin and clopidogrel testament still experience some sorting of problem related to a blood clot. Adding warfarin increases the likelihood of hemorrhage complications at a higher rate than anybody is comfortable with."
Alexander, along with Professor Lars Wallentin from the Uppsala Clinical Research Center in Sweden and other colleagues, studied the use of apixaban in 1,715 patients from 14 countries throughout Europe and North America world Health Organization had suffered a recent heart attack. Roughly two-thirds of the patients had undergone angioplasty to clear blocked arteries and 99 percent of them were taking either aspirin or aspirin and clopidogrel.
The study (called APPRAISE) was designed to identify the optimum dose of apixaban. Participants were randomised into one of four-spot doses of apixaban or a placebo. Researchers tracked the incidence of bleeding and perennial heart attack, stroke, chest of drawers pain requiring hospitalization or additional procedures or end from cardiovascular problems for the following six months.
At the death of the study, researchers discovered a non-statistically substantial trend suggesting that patients taking apixaban along with their even treatment had a lower incidence of heart attack, stroke, chest pain or death from cardiovascular problems than patients taking a placebo.
But hemorrhage was an issue, especially among those taking the higher doses of the drug (10 milligrams doubly daily or 20 milligrams once everyday). Investigators discontinued those two arms of the work because patients were experiencing unacceptable rates of hemorrhage. Patients in the leftover arms of the study (2.5 milligrams twice daily or 10 milligrams once day-to-day) also experient more hemorrhage than those taking a placebo.
Investigators say that while the results are non conclusive, they do endorsement further study.
"The data testify adding 5 or 10 milligrams of apixaban to a regimen of st. Joseph or aspirin and clopidogrel in patients hoping to prevent a second heart attack english hawthorn offer therapeutical potential," says Alexander. "But this of necessity to be definitively demonstrated in a statistically meaning manner in large, well-controlled studies."
Notes:
Apixaban is under development at Bristol-Myers Squibb, the company that sponsored the study. Alexander and Wallentin have both received enquiry support from Bristol-Myers Squibb.
Authors:
Professor John Alexander
http://www.duke.edu
This press release accompanies both a presentation and an ESC weigh conference given at the ESC Congress 2008. Written by the investigator himself/herself, this contract release does not inevitably reflect the opinion of the European Society of Cardiology.
Source:
ESC Press Office
European Society of Cardiology
View drug information on PLAVIX; Warfarin Sodium tablets.
More information
Saturday, 6 September 2008
Wednesday, 27 August 2008
Ricky Martin - Cardinal Attacks Martin Over Twins
RICKY MARTIN's baby news hasn't been well received by everyone - one leading Latino Catholic cardinal has slammed the pour down star for acting without dignity.
The Puerto Rican isaac Merrit Singer recently fathered twin boys, born to a surrogate mother, world Health Organization is rumoured to be a cousin-german of the singer.
And, following on from congratulations from his pop peers, those who aren't happy around Martin's raw paternal role are speech production out straightaway.
The cardinal of Honduras, Oscar Andres Rodriguez, accuses the singer of going against human lordliness.
On a bring down to Chile, the Catholic leader aforementioned, "What Martin did diminishes the dignity of a human organism. You can't just buy or economic rent life. It's even worse when someone famous and in the public eye is doing it."
And he isn't alone - Mexican talk show host Esteban Arce has also spoken out against Martin.
On his show Matutino Express, Arce aforementioned, "I don't think it's right to deny children of parental figures, precisely because you have a big egotism."
More information
Monday, 18 August 2008
Using Animals In Pain Research Has Limited Value Say Scientists
�A panel of UK experts aforesaid using animals in painful sensation research has limited value and they should be replaced by neuroimaging techniques based on
fMRI, PET and other scanning technologies combined with new approaches such as genome-wide association and tissue research.
The instrument panel members, world Health Organization come from London, Manchester, Liverpool and Oxford, attended a shop called "Focus on Alternatives", which was
arranged by organizations funding alternatives to animal experiments, such as the RSPCA and the UK Human Tissues Bank. The results,
conclusions and recommendations of the workshop are reported in the 15 August issue of the journal Neuroimage.
UK scientists are compulsory by law to weigh non-animal approaches when designing new experiments. Animal
experiments in pain in the neck research sometimes use animals while they are conscious, and sometimes while under anaesthesia.
Although at that place have been a band of studies on human pain disorder, safe and effective treatments are still hard to find; yet animal models, some of
which take limited value, because they don't duplicate the processes of human pain, still dominate research and they raise ethical questions.
This is despite the opportunities offered by new technologies, particularly in the field of neuroimaging. According to the authors, the workshop
explored in a creative way, "the tools, strategies and challenges of replacement some creature experiments in pain research with ethically conducted
studies of human patients and healthy volunteers, in combination with in vitro methods".
The panel members looked at how unexampled neuroimaging techniques including functional magnetic sonority imaging (fMRI),
magnetoencephalography and positron emission tomography (PET), on their own or in combination, could be used to investigate human pain
conditions.
They ended there were lots of opportunities too to combine these methods with other techniques such as microdialysis (a lowly probe that
detects chemicals in the spaces betwixt cells in tissue), genome-wide association enquiry (looking at genetic differences between people),
studies on twins, and tissue research.
One of the co-authors, Professor Qasim Aziz, who is based at Barts and the London School of Medicine and Dentistry told the BBC that he used
neuroimaging techniques to explore the brains of patients with a ambit of pain sensation disorders such as irritable bowel and unexplained chest of drawers pain to work
out how the brain uses pain signals.
Aziz said that "new and highly sophisticated brain-imaging engineering is providing vital insights that fauna research has failed to produce". He wants
to see more scientists exploitation these methods, although he does unruffled see a need for animals in a limited sense, for instance in drug dose
experiments.
"Volunteer studies in pain research -- Opportunities and challenges to replace creature experiments: The report and recommendations of a
Focus on Alternatives workshop."
C.K. Langley, Q. Aziz, C. Bountra, N. Gordon, P. Hawkins, A. Jones, G. Langley, T. Nurmikko, I. Tracey.
NeuroImage, Volume 42, Issue 2, 15 August 2008, Pages 467-473.
DOI: 10.1016/j.neuroimage.2008.05.030.
Click here for Abstract.
Sources: Journal abstract, BBC.
Written by: Catharine Paddock, PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
fMRI, PET and other scanning technologies combined with new approaches such as genome-wide association and tissue research.
The instrument panel members, world Health Organization come from London, Manchester, Liverpool and Oxford, attended a shop called "Focus on Alternatives", which was
arranged by organizations funding alternatives to animal experiments, such as the RSPCA and the UK Human Tissues Bank. The results,
conclusions and recommendations of the workshop are reported in the 15 August issue of the journal Neuroimage.
UK scientists are compulsory by law to weigh non-animal approaches when designing new experiments. Animal
experiments in pain in the neck research sometimes use animals while they are conscious, and sometimes while under anaesthesia.
Although at that place have been a band of studies on human pain disorder, safe and effective treatments are still hard to find; yet animal models, some of
which take limited value, because they don't duplicate the processes of human pain, still dominate research and they raise ethical questions.
This is despite the opportunities offered by new technologies, particularly in the field of neuroimaging. According to the authors, the workshop
explored in a creative way, "the tools, strategies and challenges of replacement some creature experiments in pain research with ethically conducted
studies of human patients and healthy volunteers, in combination with in vitro methods".
The panel members looked at how unexampled neuroimaging techniques including functional magnetic sonority imaging (fMRI),
magnetoencephalography and positron emission tomography (PET), on their own or in combination, could be used to investigate human pain
conditions.
They ended there were lots of opportunities too to combine these methods with other techniques such as microdialysis (a lowly probe that
detects chemicals in the spaces betwixt cells in tissue), genome-wide association enquiry (looking at genetic differences between people),
studies on twins, and tissue research.
One of the co-authors, Professor Qasim Aziz, who is based at Barts and the London School of Medicine and Dentistry told the BBC that he used
neuroimaging techniques to explore the brains of patients with a ambit of pain sensation disorders such as irritable bowel and unexplained chest of drawers pain to work
out how the brain uses pain signals.
Aziz said that "new and highly sophisticated brain-imaging engineering is providing vital insights that fauna research has failed to produce". He wants
to see more scientists exploitation these methods, although he does unruffled see a need for animals in a limited sense, for instance in drug dose
experiments.
"Volunteer studies in pain research -- Opportunities and challenges to replace creature experiments: The report and recommendations of a
Focus on Alternatives workshop."
C.K. Langley, Q. Aziz, C. Bountra, N. Gordon, P. Hawkins, A. Jones, G. Langley, T. Nurmikko, I. Tracey.
NeuroImage, Volume 42, Issue 2, 15 August 2008, Pages 467-473.
DOI: 10.1016/j.neuroimage.2008.05.030.
Click here for Abstract.
Sources: Journal abstract, BBC.
Written by: Catharine Paddock, PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
Friday, 8 August 2008
Joe Budden
Artist: Joe Budden
Genre(s):
Other
Rap: Hip-Hop
Discography:
Im Back
Year: 2005
Tracks: 22
Joe Budden
Year: 2003
Tracks: 17
Mood Muzik 2 (Can It Get Any Worse?)
Year:
Tracks: 20
The hapless success of 50 Cent in early 2003 open the floodgates for other street-level, mixtape-bred rappers, one of whom was Joe Budden, a Jersey City rapper with a decided loose cannon style molded from days of freestyling. Born in Spanish Harlem and raised in Queens, Budden came of eld across the Hudson River in Jersey City, which he proudly continued to repp in his rhymes despite its passably distasteful reputation relation to more traditional rap gentility grounds like Harlem, Brooklyn, the South Bronx, and Queensbridge. Following some troubled teen days that included a erolia minutilla of sizable dose ill-treat, Budden cleaned himself up and focussed his sights on hip-hop fame. He teamed up with producer Dub-B (aka White Boy) and began devising demos, one of which terminated up in the hands of DJ Clue. Soon afterward, Budden was a mixtape fixture, freestyling over pop beat generation on mixes by New York's star DJs, to the highest degree notably Clue, DJ Kayslay, and Cutmaster C. In particular, his "Grindin'" freestyle off heads, as did one of his White Boy productions, "Focus." It wasn't long earlier Budden united On Top direction and went to do work with Just Blaze, one of New York's hottest producers of the instantaneous, topper known for his work with Jay-Z simply besides respected for his sure-fire mercenary do work, such as Erick Sermon's "Respond" and Cam'ron's "Oh Boy." Indeed, a sure-fire attain resulted: "Pump It Up," a club-ready track that connected all over, from MTV to the streets. While all of this was going down, industry hulk Def Jam signed Budden and prepared his self-titled debut record album, which charted well its opening hebdomad, earned some critical fiscal backing, and foreshadowed a bright succeeding for the refreshingly unique rapper.
Tuesday, 1 July 2008
Estelle
Artist: Estelle
Genre(s):
Rap: Hip-Hop
Discography:
The 18th Day
Year: 2004
Tracks: 14
Able to rap, sing, and write songs that have everyone from John Legend to Roots Manuva tattle her praises, U.K. MC Estelle got her start in London's notable hip-hop record shop Deal Real. Her fellow employees bucked up her to take a probability and catch on the microphone onstage; presently she was playacting numerous London clubs and appearance with the likes of Manuva and Rodney P. Local hero Skitz asked her to seem on his 2000 album, Countryman, and presently she landed on albums by the likes of the 57th Dynasty and Blak Twang. She made her solo debut in 2003 with the Excuse Me 12" on the Paradise Isle label, simply her breakthrough trail came in 2004 when 1980 was released by the V2 label. A street-level mixtape series called Da Heat and further 12"s like Relinquish and Go Gone helped build a truehearted following, and Estelle gave back to the U.K. rap scene by forming her have Stellarents label to sign new artists. Late in 2004 V2 released her debut album, The 18th Day, which made a heavy encroachment in the U.K. In 2007 U.S. R&B singer John Legend proclaimed that Estelle would be the first signee to his Homeschool label, distributed by Atlantic. The label scheduled her soph album, Shine, for early 2008.
Wednesday, 18 June 2008
Architect
Artist: Architect
Genre(s):
Electronic
Discography:
I Went Out Shopping To Get Some Noise Digipak
Year: 2004
Tracks: 13
The Galactic Supermarket
Year: 1999
Tracks: 11
Galactic Edge
Year: 1998
Tracks: 6
Monday, 9 June 2008
The Police to play last-ever show at Madison Square Garden
The Police have announced they will play their last-ever show at Madison Square Garden in New York City, with support from the B52s.
The band will perform the gig on August 7, with all proceeds from the show going to New York public television stations Thirteen/WNET and WLIW21.
In order to secure tickets to the event, fans can make donations to the stations from June 14, when the stations will air a Police special. The price of the tickets, which will be sold in pairs, will range from $150 to $5,000. The latter is a package deal that includes admission to the sound check.
Members of The Police fanclub will have the opportunity to buy tickets from Monday (June 9)
The band announced the show a month ago on May 6, when they donated $1 million to New York Mayor Michael Bloomberg's programme that will see one million trees planted in the city by 2017. The city matched the band's contribution.
--By our New York staff.
Find out more about NME.
Jun 29, 2008 at Hyde Park, London -
More The Police tickets
The band will perform the gig on August 7, with all proceeds from the show going to New York public television stations Thirteen/WNET and WLIW21.
In order to secure tickets to the event, fans can make donations to the stations from June 14, when the stations will air a Police special. The price of the tickets, which will be sold in pairs, will range from $150 to $5,000. The latter is a package deal that includes admission to the sound check.
Members of The Police fanclub will have the opportunity to buy tickets from Monday (June 9)
The band announced the show a month ago on May 6, when they donated $1 million to New York Mayor Michael Bloomberg's programme that will see one million trees planted in the city by 2017. The city matched the band's contribution.
--By our New York staff.
Find out more about NME.
Jun 29, 2008 at Hyde Park, London -
More The Police tickets
Subscribe to:
Posts (Atom)